Ụlọ ọrụ teknụzụ BEIJING SUCCEEDER INC.

Ndị na-aṅụ ọgwụ ndị na-ebelata ọbara kwesịrị ịkpachara anya mgbe ha na-eri unere. Beijing Succeeder na-enyere aka na nchọpụta thrombosis na hemostasis.

A na-ewere unere dị ka mkpụrụ osisi dị mma n'ihi na ọ bara ụba n'ihe oriri, gụnyere vitamin na mineral. Agbanyeghị, maka ndị na-aṅụ ọgwụ ndị na-ebelata ọbara, unere nwere ike ibute ihe egwu zoro ezo maka ahụike.

A na-ejikarị ọgwụ ndị na-ebelata ọbara, dị ka warfarin nkịtị, egbochi ma gwọọ nsogbu thrombosis. Ndị ọrịa nwere nsogbu dịka ịwa ahụ mgbanwe valvụ obi, ịwa ahụ atrial fibrillation, na thrombosis venous venous thrombosis na-achọkarị iji ya ogologo oge. Usoro ha si eme ihe bụ igbochi mkpali nke ihe ndị na-akpata coagulation dabere na vitamin K, si otú a belata ihe ize ndụ nke coagulation ọbara ma hụ na ọbara na-agagharị nke ọma. Unere bụ mkpụrụ osisi bara ụba na vitamin K, nke nwere ihe dị ka maịkrogram 10 kwa gram 100. Vitamin K na-arụ ọrụ dị ka "ihe na-akpali" nke usoro coagulation, na-akwalite mkpali nke ihe ndị na-akpata coagulation ma na-eme ka coagulation ọbara dịkwuo ngwa ngwa. Mgbe ndị ọrịa na-aṅụ ọgwụ ndị na-ebelata ọbara na-eri nnukwu unere, ọkwa vitamin K ha na-abawanye nke ukwuu. Nke a nwere ike igbochi mmetụta nke ọgwụ ahụ, na-ebelata irè nke ihe ndị na-ebelata ọbara ma na-amụba nke ukwuu ohere nke coagulation ọbara. Onye ọrịa nwere ọbara mgbali elu nke na-aṅụ warfarin ruo afọ atọ nwetara ihe nrịbama coagulation a na-achịkwaghị achịkwa mgbe ọ ṅụsịrị unere smoothie na nri ụtụtụ ruo otu izu, nke mechara mee ka ọ gaa ụlọ ọgwụ maka strok. Okwu a na-eje ozi dị ka oku maka ndị ọrịa na-aṅụ ọgwụ ndị na-ebelata ọbara.

Agbanyeghị, nke a apụtaghị na ndị na-aṅụ ọgwụ ndị na-ebelata ọbara kwesịrị izere unere kpamkpam. Dịka "Ntuziaka Nri maka Ndị Bi na China (2022) si kwuo, ndị okenye kwesịrị iri gram 200-350 nke mkpụrụ osisi kwa ụbọchị, ihe dị ka otu unere ruo abụọ. Iri obere nri anaghị emetụta arụmọrụ nke ọgwụ ndị na-ebelata ọbara nke ukwuu. Agbanyeghị, isi ihe dị mkpa bụ ịnọgide na-enwe nri kwesịrị ekwesị ma kwụsie ike ma zere nnukwu mgbanwe na oriri vitamin K n'ime obere oge.

Beijing Succeeder Technology Inc. (koodu ngwaahịa: 688338) bụ onye ndu n'ihe gbasara nchọpụta in vitro maka thrombosis na hemostasis. E hiwere ụlọ ọrụ a na 2003, ọ lekwasịkwara anya ruo ọtụtụ afọ na nyocha, mmepe, mmepụta, na ire ngwa nyocha in vitro na reagents maka thrombosis na hemostasis. Beijing Succeeder na-enye ụlọ ọrụ ahụike ngwa nnwale akpaaka, gụnyere coagulation, hemorheology, hematocrit, na nchịkọta platelet, yana ihe ndị na-akwado reagents na ihe oriri. A na-eji ngwaahịa ya eme ihe nke ukwuu na mgbochi, nyocha, nchọpụta, na nlekota ọrịa thrombotic na hemorrhagic, gụnyere strok, ọrịa akwara obi, na thromboembolism venous.

Na 2023, ihe nyocha coagulation nke Beijing Succeeder nke ọma nwetara ndebanye aha CE nke IVDR, na-egosikwa ike teknụzụ ya na ịdị mma nke ngwaahịa ya na ngalaba nchọpụta in vitro. Data ewepụtara na August 17 nke otu afọ ahụ gosiri na ụlọ ọrụ ahụ nwetara ego ọrụ nke nde yuan 141 na ọkara mbụ nke afọ ahụ, mmụba kwa afọ nke 33.19%, na uru net nke ndị nwere òkè nke nde yuan 60.222, mmụba kwa afọ nke 26.91%. Ọzọkwa, Beijing Succeeder enwetala ọtụtụ nsọpụrụ, gụnyere ịbụ onye a họpụtara maka Ndepụta Ọrụ Torch nke Mba 2012 nke Torch Center nke Ministry of Science and Technology bipụtara, ma nọrọ n'ọkwa nke 29 na 2022 China In Vitro Diagnostic Industry Listed Net Profit Ranking Company.

Beijing Succeeder, tinyere ngwaahịa na teknụzụ ọkachamara ya, na-enye nkwado siri ike nye ndị dọkịta iji nyochaa ọnọdụ coagulation nke ndị ọrịa nke ọma, na-arụ ọrụ dị mkpa n'ichebe ahụike onye ọrịa. Maka ndị ọrịa na-aṅụ ihe na-ebelata ọbara, nlekota oge niile site na iji teknụzụ na ngwaahịa nnwale dị elu, ebe ị na-elebara mmekọrịta nri na ọgwụ anya, nwere ike ime ka ọgwụgwọ dịkwuo irè ma nwee ahụike zuru oke.